



Information Disclosure Statement By Applicant Page 1 of 2	Docket: SEQ-2	PATENT
	Title: Cancer Immunotherapy Using Autologous Tumor Cells Combined with Allogeneic Cytokine-Secreting Cells	U.S.S.N. 09/162,648
	Inventor: J.C. Hiserodt	Art Unit: 1633
Filing Date: November 29, 1998	Examiner: Carrie Stroup, Ph.D	

U.S. Patent Documents

Examiner Initial	Ref	Patent	Filing Date	Issue Date	Class/ Subclass	Inventors	Title

Foreign Patents and Published Foreign Patent Applications

Examiner Initial	Ref	Serial No.	Publication Date	Juris-diction	Title	Translation	
						Yes	No
(MS)	A	WO 99/18981	Apr 22/99	PCT	Implants Comprising Combinations of Allogeneic Cells for Use in Cancer Treatment (Having priority to USCN 20/001-700, Serial No. 09/162,648)	<input checked="" type="checkbox"/>	
(MS)	B	WO 99/19462	Apr 22/99	PCT	Enhanced Immunogenic Cell Populations Prepared Using Fc Receptor Antagonists	<input checked="" type="checkbox"/>	

Other Documents

Examiner Initial	Ref.	Description of Item
(MS)	C	Declaration by Tetsuya Gatanaga Pursuant to 37 CFR § 1.56 Regarding Clinical Trial Conducted under IND-6288 (5 pages)
(MS)	D	Appendix A to Declaration by Tetsuya Gatanaga: Curriculum Vitae (15 pages)
(MS)	E	Appendix B to Declaration by Tetsuya Gatanaga: Data from Clinical Trial, Protocol AIT-PAN-20 (12 pages)
	F	Storniolo et al., Cancer 15:1261-8, 1999. "An investigational new drug treatment program with gemcitabine: results for over 3000 patients with pancreatic cancer." (Complete article)
(MS)	G	Hidalgo et al., J. Clin. Oncol. 17:585-92, 1999. "Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer" (Abstract only)
(MS)	H	Dugan et al., Pancreas 17:325-33, 1998. "Current concepts in pancreatic cancer: Symposium summary" (Abstract only)
(MS)	I	Stephens, Oncol. Nurs. Forum 25:87-93, 1998. "Gemcitabine: A new approach to treating pancreatic cancer" (Abstract only)
(MS)	J	Carmichael, Digestion 58:503-7, 1997. "Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine" (Abstract only)
(MS)	K	Burris et al., Eur. J. Cancer 33:S18-22, 1997. "Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil" (Abstract only)
(MS)	L	Rotherberg et al., Ann. Oncol. 7:347-53, 1996. "A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer" (Abstract only)
(MS)	M	Carmichael et al., Br. J. Cancer 73:101-5, 1996. "Phase II study of gemcitabine in patients with advanced pancreatic cancer" (Abstract only)

9/21/00



Information Disclosure Statement By Applicant		Doc. Ref.: SEQ-2	PATENT
		Title: Cancer Immunotherapy Using Autologous Tumor Cells Combined with Allogeneic Cytokine-Secreting Cells	U.S.S.N. 09/162,648
Page 2 of 2		Inventor: J.C. Hiserodt	Art Unit: 1633
		Filing Date: November 29, 1998	Examiner: Carrie Stroup, Ph.D

Other Documents

Examiner Initial	Ref	Description of Item
<i>MJS</i>	N	Casper et al., Invest. New Drugs 12:29-34, 1994. "Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas" (Abstract only)
<i>MJS</i>	O	Burris et al., J. Clin. Oncol. 15:2403-13, 1997. "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial" (Abstract only)
<i>MJS</i>	P	Michael et al., Oncology (Huntingt) 11:1615-22, 1625-7, 1997. "Clinical experience with gemcitabine in pancreatic carcinoma" (Abstract only)

Examiner <i>Carrie Stroup</i>	Date Considered <i>6/12/00</i>
----------------------------------	-----------------------------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.